Home    | Feature Article  |  E-ahead of Print   |  Archives   | Author Guidline   | Editorial Board

About the Journal of Applied Virology  
 Journal of Applied Virology (J. Appl. Virol. Print ISSN: 2305-5154; Online ISSN: 2306-6210) is an open access, peer- reviewed journal that considers articles on all aspects of virology, including research on viruses of human, animals, plants, bacteria and fungi. The journal also considers articles on biological products, especially for viral vaccine, etc. The journal welcomes research articles as following:
  • Virion structure and assembly,
  • Viral genome replication and regulation of gene expression,
  • Genetic diversity and evolution,
  • Viral pathogenesis and immunity,
  • Viral vaccines and antiviral agents,
  • Virus-cell interactions, cellular responses to infection,
  • Transformation and oncogenesis,
  • Gene delivery and molecular biochemistry,
  • Novel methods on virology and pre-clinical and clinical studies of anti-viral therapies.

 

Crrent Issues    Number 4  Volume 9

Articles @ Virology

Ruxia Ding, Haixin Wang, Yi Yang, Liangshu Xie, Li Zhang, Qianqian Li, Shuo Liu, Jianhui Nie, Jiajing Wu, Haiyang Qin, Yuelei Shen, Huiguo Wang, Weijin Huang, Youchun Wang

 

Abstract


 

The dominant N501Y mutation in the spike protein that SARS-CoV-2 virus uses to bind to the human ACE2 receptor were found in the UK, which has aroused global concern and worried. Mutations in spike protein may, in theory, result in more infectious and spreading more easily. In order to evaluate the broad-spectrum protective effect of the monoclonal antibodies(mAbs), we compared the neutralization activities of six prepared mAbs against SARS-CoV-2 with pseudovirus neutralization assay. Only one of them showed a decrease of 6 folds in neutralizing activity to N501Y mutant strain, compared with the wild type strain. We should continue to monitor emergence of new variants in different regions to study their infectivity and neutralization effect.


 

Keywords


 
COVID-19, SARS-CoV-2, Mutation, Antibody

 

Full Text:

PDF


DOI: https://doi.org/10.21092/jav.v9i4.90

 

Number 3 Volume 9
Yu Bi, Zheng Pang, Lijun Shao, Yunfeng Tang, Guoyu Niu

 

Abstract


 

Yellow fever (YF) is an acute infectious disease caused by yellow fever virus (YFV), which is one of the three infectious diseases of international health regulations. We tested people from epidemic areas of Tianjin port in 2014 to investigate the prevalence and distribution characteristics of yellow fever virus antibody. 192 samples were collected and the positive rate of yellow fever virus antibody was 22.92%. The positive rates among different countries, genders, ages, occupations and entry time were calculated and analyzed. There were significant difference in the detection rate of YFV antibody among people with different age groups and occupations. The positive rate of people >40 age and workers engaged in labor were relatively high and had statistical significance compared to other groups.


 

Keywords


 
Yellow Fever, Virus, Antibody, Human Serum, Epidemic Areas

 

Full Text:

PDF


DOI: https://doi.org/10.21092/jav.v9i3.89

 

Number 2  Volume 9   

Articles @ Virology

Min Xue Ji, Xiang Qun Li, Cui Liu

 

Abstract


 

With the application of new technologies in development and production, the quality of vaccines in China had been constantly improved, and vaccines manufactured in China were being supplied to international markets while meeting the domestic immunization program need. Meanwhile, the quality management performance of vaccine manufacturers in China was continually improving. The implementation of the Vaccine Administration Law of the People¨s Republic of China had imposed legal systematic requirements on full lifecycle management of vaccines in development, production and supervision, which was of important milestone significance for guiding the development of China¨s vaccine industry. Based on the understanding of this law, this article had discussed quality management of vaccines from four aspects including biosafety, application of new technologies for vaccine development and production, process changes and deviation management with practical work taken into account, intended to arouse readers¨attention and discussions on this law and relevant issues and provide reference to vaccine manufacturers in production, development and product quality improvement.


 

Keywords


 
Vaccine Administration Law of the People¨s Republic of China, Vaccine, Biosafety, New technology, Process change, Deviation management

 

Full Text:

PDF


DOI: 
https://doi.org/10.21092/jav.v9i2.88
 
ABOUT THE AUTHORS

Min Xue Ji
Beijing Minhai Biological Technology Co., Ltd., Beijing, 102629, P.R.China
China

 

 

Xiang Qun Li
Beijing Minhai Biological Technology Co., Ltd., Beijing, 102629, P.R.China
China

 

 

Cui Liu
Beijing Minhai Biological Technology Co., Ltd., Beijing, 102629, P.R.China
China

 

 
 
 
 Number 1  Volume 9

Articles @ Virology

Yue Zhang, Huijie Chen, Nicole Pirozzi, Yingying Cong

 

Abstract


 

Coronavirus (CoV), is a single-stranded positive-sense RNA virus, which is characterized by a coronal-shaped spinous process on its surface and is the largest known RNA virus. Recently, the new outbreak of CoV was first found in Wuhan, China at the end of 2019, however, the infection is worldwide and causing high pathogenicity and mortality rates, especially in the aged population. Unfortunately, there is no available strategy to control the infection or treat patients. By reviewing the life cycle of CoV infection in host cells, including: virion attachment and entry, genome transcription and replication, and virion assembly and release, we focused on the role of viral proteins in the viral life cycle and summarized how their function could be targeted for the prevention/therapy of CoV. Thus, this information would pave the way to precisely design the antiviral drug component/vaccine against CoVs.


 

Keywords


 
Coronavirus, Anti-viral strategy, Review

 

Full Text:

PDF


DOI: 
https://doi.org/10.21092/jav.v9i1.87
 
ABOUT THE AUTHORS

Yue Zhang 
College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, P.R.China
China

 

 

Huijie Chen 
College of Biological and Pharmaceutical Engineering, Jilin Agricultural Science and Technology University, Jilin 132101, P.R. China
China

 

 

Nicole Pirozzi 
Department of Biomedical Sciences of Cells & Systems, University Medical Center Groningen, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands
Netherlands

 

 

Yingying Cong 
Department of Biomedical Sciences of Cells & Systems, University Medical Center Groningen, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands
Netherlands

 
 
 
Manuscript Tracking System
   
 

 

Submit Manuscript
  • The author should register as authour firstly by click the follows link.

 

  • Submit your article by login in the Manuscript Tracking System with your username and password.

 

 

Editorial Team

Honorary Chief Editor

Prof. Farhad Imani :ViraSource Laboratories, North Carolina,27709, USA

Chief Editor  

Dr.  Wenbo Zhang:North Carolina State Laboratory Of Public Health, Raleigh, North Carolina, USA

 Dr. Kongxin Hu:Chinese Academy of Inspection and Quarantine, China

Associate Chief Editor  

Dr. Tengchuan Jin: University of Science and Technology of China

Dr.  Tao Wang : School of Life Sciences,Tianjin University , China

Dr.  Fushun Zhang: The University of Texas Health Science Center at San Antonio, Texas, USA

Managing Director  

Dr.  Kai Wang:Institut Pasteur of Shanghai, Chinese Academy of Sciences, China

 

Abstracted/Indexed in
 

Google Scholar
    http://scholar.google.com/

  CrossRef

Index Copernicus

Directory of Open Access Journals (DOAJ)

  
NewJour
CiteFactor:

WorldCat

JournalTOC:

JournalSeek

CAB Abstracts

Baidu Scholar

Publons

JournalGuide

 

All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2012-2021 All rights reserved